CA2016841C - Methode de production de polymeres ayant une activite choisie - Google Patents

Methode de production de polymeres ayant une activite choisie

Info

Publication number
CA2016841C
CA2016841C CA 2016841 CA2016841A CA2016841C CA 2016841 C CA2016841 C CA 2016841C CA 2016841 CA2016841 CA 2016841 CA 2016841 A CA2016841 A CA 2016841A CA 2016841 C CA2016841 C CA 2016841C
Authority
CA
Canada
Prior art keywords
coding
primers
dna
antibody
repertoire
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA 2016841
Other languages
English (en)
Other versions
CA2016841A1 (fr
Inventor
William D. Huse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Clinic and Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic and Research Foundation filed Critical Scripps Clinic and Research Foundation
Publication of CA2016841A1 publication Critical patent/CA2016841A1/fr
Application granted granted Critical
Publication of CA2016841C publication Critical patent/CA2016841C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA 2016841 1989-05-16 1990-05-15 Methode de production de polymeres ayant une activite choisie Expired - Lifetime CA2016841C (fr)

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US35323589A 1989-05-16 1989-05-16
US35292789A 1989-05-16 1989-05-16
US07/353,235 1989-05-16
US07/352,927 1989-05-16
US35288489A 1989-05-17 1989-05-17
US35324189A 1989-05-17 1989-05-17
US07/353,241 1989-05-17
US07/352,884 1989-05-17
US41073589A 1989-09-20 1989-09-20
US41074989A 1989-09-20 1989-09-20
US41088889A 1989-09-20 1989-09-20
US41071689A 1989-09-20 1989-09-20
US07/410,716 1989-09-20
US07/410,735 1989-09-20
US07/410,888 1989-09-20
US07/410,749 1989-09-20
US41105889A 1989-09-21 1989-09-21
US07/411,058 1989-09-21
US44633389A 1989-12-04 1989-12-04
US07/446,333 1989-12-04
US49710690A 1990-03-20 1990-03-20
US07/497,106 1990-03-20

Publications (2)

Publication Number Publication Date
CA2016841A1 CA2016841A1 (fr) 1990-11-16
CA2016841C true CA2016841C (fr) 1999-09-21

Family

ID=27582782

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2016841 Expired - Lifetime CA2016841C (fr) 1989-05-16 1990-05-15 Methode de production de polymeres ayant une activite choisie

Country Status (6)

Country Link
EP (1) EP0472638B1 (fr)
JP (1) JP3321159B2 (fr)
AU (1) AU651065B2 (fr)
CA (1) CA2016841C (fr)
PT (1) PT94066B (fr)
WO (1) WO1990014424A1 (fr)

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993813A (en) * 1988-10-19 1999-11-30 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
US6641999B1 (en) 1988-10-19 2003-11-04 The Dow Chemical Company Probing method for identifying antibodies specific for selected antigens
US6051225A (en) 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
CA2016842A1 (fr) * 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
ATE449853T1 (de) † 1990-02-01 2009-12-15 Siemens Healthcare Diagnostics HERSTELLUNG UND VERWENDUNG VON GENBANKEN MENSCHLICHER ANTIKÖRPER(ßHUMAN-ANTIKÖRPER- BIBLIOTHEKENß)
AU7791991A (en) * 1990-04-24 1991-11-11 Stratagene Methods for phenotype creation from multiple gene populations
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (fr) * 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
IL99552A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE69131017T2 (de) * 1990-12-20 1999-07-15 Ixsys, Inc., San Diego, Calif. Optimierung von bindenden proteinen
US5955341A (en) * 1991-04-10 1999-09-21 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
AU662148B2 (en) * 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) * 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
DK1696031T3 (da) * 1991-12-02 2010-08-02 Medimmune Ltd Fremstilling af anti-autoantigener fra antistofsegmentrepertoirer og præsentere på fag
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JP3949712B2 (ja) * 1991-12-02 2007-07-25 メディカル リサーチ カウンシル 抗体セグメントレパートリー由来でファージに表示される抗自己抗体の産生
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994005781A1 (fr) * 1992-09-04 1994-03-17 The Scripps Research Institute Phagemides coexprimant un recepteur de surface et une proteine heterologue de surface
AU6235294A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing polypeptide binding sites
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6165793A (en) * 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6054567A (en) 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
EP1030861A4 (fr) 1997-10-31 2001-09-05 Maxygen Inc Modification du tropisme viral et de la diversite d'especes hote par recombinaison du genome viral
AU746786B2 (en) 1997-12-08 2002-05-02 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
CA2362737A1 (fr) 1999-03-05 2000-09-08 Maxygen, Inc. Recombinaison d'acides nucleiques d'insertion modifies
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP2311951A1 (fr) 2000-01-28 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Nouveaux épitopes de lymphocytes T restreints de classe II de MHC pour l'antigène de cancer, NY ESO-1
WO2001093905A1 (fr) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Oligonucleotides synthetiques immunostimulatoires
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
CA2429544C (fr) 2000-11-17 2010-10-19 University Of Rochester Methodes in vitro de production et d'identification de molecules d'immunoglobulines dans des cellules eucaryotiques
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
RU2318829C2 (ru) 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
SI2508596T1 (sl) 2002-02-21 2016-01-29 Institute Of Virology Slovak Academy Of Sciences Monoklonska protitelesa, specifična za MN/CA IX, proizvedena iz MN/CA IX deficientnih miši, in postopki uporabe
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP2452694B1 (fr) 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anticorps anti-IL-23, compositions, procédés et utilisations
CN103146708A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
EP2500353A3 (fr) 2005-08-19 2012-10-10 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
RS55963B1 (sr) 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
PL3339445T3 (pl) 2006-09-08 2020-12-14 Abbvie Bahamas Ltd. Białka wiążące interleukinę 13
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (fr) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
WO2009055656A2 (fr) 2007-10-26 2009-04-30 Centocor, Inc. Vecteurs, cellules hôtes, procédés de production et utilisations
WO2009067546A2 (fr) 2007-11-19 2009-05-28 Celera Corpration Marqueurs de cancer du poumon et leurs utilisations
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
RU2518351C2 (ru) 2008-05-09 2014-06-10 Эббви Дойчланд Гмбх Унд Ко.Кг, Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
EP3002299A1 (fr) 2008-06-03 2016-04-06 AbbVie Inc. Immunoglobulines à deux domaines variables et leurs utilisations
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
CN102369217A (zh) 2009-01-29 2012-03-07 雅培制药有限公司 Il-1结合蛋白
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
AU2010249470B2 (en) 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
WO2010136598A1 (fr) 2009-05-29 2010-12-02 Morphosys Ag Collection et ses procédés d'utilisation
US8623358B2 (en) 2009-08-29 2014-01-07 Abbvie Inc. Therapeutic DLL4 binding proteins
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (fr) 2009-10-31 2011-05-05 Abbott Laboratories Anticorps pour récepteur pour produits terminaux de glycation avancée (rage) et utilisations de ceux-ci
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
EP2542582A4 (fr) 2010-03-02 2013-12-04 Abbvie Inc Protéines thérapeutiques de liaison à dll4
LT2552961T (lt) 2010-03-30 2018-02-12 Janssen Biotech, Inc. Humanizuoti il-25 antikūnai
EP2558494B1 (fr) 2010-04-15 2018-05-23 AbbVie Inc. Protéines de liaison à la bêta amyloïde
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
WO2012006500A2 (fr) 2010-07-08 2012-01-12 Abbott Laboratories Anticorps monoclonaux contre la protéine de capside du virus de l'hépatite c
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
WO2012024650A2 (fr) 2010-08-19 2012-02-23 Abbott Laboratories Anticorps anti-ngf et leur utilisation
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
HRP20181811T1 (hr) 2010-11-19 2018-12-28 Morphosys Ag Zbirka sljedova protutijela i njezina upotreba
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
WO2012121775A2 (fr) 2010-12-21 2012-09-13 Abbott Laboratories Immunoglobulines à double domaine variable et leurs utilisations
MX344595B (es) 2010-12-31 2016-12-20 Bioatla Llc Humanizacion rapida de anticuerpos.
RU2640025C2 (ru) 2011-07-13 2017-12-25 Эббви Инк. Способы и композиции для лечения астмы с использованием антител против il-13
EP2771360A1 (fr) 2011-10-24 2014-09-03 AbbVie Inc. Agents de liaison immunologique dirigés contre la sclérostine
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
EP3369746A1 (fr) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition et procédé pour le diagnostic et le traitement de maladies associées à la dégénérescence des neurites
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
KR20150046316A (ko) 2012-08-31 2015-04-29 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
WO2014100542A1 (fr) 2012-12-21 2014-06-26 Abbvie, Inc. Humanisation d'anticorps à haut rendement
EP2970947A4 (fr) 2013-03-14 2016-10-12 Abbott Lab Antigènes recombinants ns3 de vhc et leurs mutants pour la détection d'anticorps améliorée
JP6505076B2 (ja) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
CN105378099B (zh) 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
EP2970459A2 (fr) 2013-03-15 2016-01-20 AbbVie Inc. Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1beta et il -17
PT3038650T (pt) 2013-08-30 2021-08-25 Immunogen Inc Anticorpos e ensaios para a deteção do recetor de folato 1
WO2015038984A2 (fr) 2013-09-12 2015-03-19 Halozyme, Inc. Anticorps anti-récepteur du facteur de croissance épidermique modifiés et procédés pour les utiliser
EP4043493A1 (fr) 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anticorps anti-vista et fragments
SI3128997T1 (sl) 2014-04-08 2020-11-30 Boston Pharmaceuticals Inc. Vezavne molekule specifične za IL-21 in njihove uporabe
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
KR102781223B1 (ko) 2014-11-10 2025-03-12 메디뮨 리미티드 Cd73에 특이적인 결합 분자 및 이의 용도
US20160129108A1 (en) 2014-11-11 2016-05-12 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CA2973978A1 (fr) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Traitement du cancer avec des anticorps monoclonaux anti-lap
RU2715597C2 (ru) 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3722314A1 (fr) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anticorps anti-vista et fragments
SMT202100092T1 (it) 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
LT3374398T (lt) 2015-11-10 2020-09-10 Medimmune, Llc Asct2 atžvilgiu specifinės surišančios molekulės ir jų panaudojimai
TW202216201A (zh) 2016-02-12 2022-05-01 比利時商楊森製藥公司 抗vista抗體及片段、其用途及鑑定其之方法
CA3015277A1 (fr) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Proteines de liaison au recepteur de l'activine de type 2 et leurs utilisations
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
EA201892190A1 (ru) 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
WO2017175058A1 (fr) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anticorps anti-vista et fragments de ceux-ci, leurs utilisations et leurs procédés d'identification
CN116217731B (zh) 2016-04-22 2025-12-30 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
PE20190622A1 (es) 2016-06-02 2019-04-26 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
CA3027044A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-b7-h3 et conjugues anticorps-medicaments
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP3519049B1 (fr) 2016-09-30 2025-12-03 Janssen Biotech, Inc. Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
MX2019005661A (es) 2016-11-16 2019-10-07 Janssen Biotech Inc Método para tratar la psoriasis con el anticuerpo específico anti-il23.
CN110662770A (zh) 2016-11-23 2020-01-07 比奥维拉迪维治疗股份有限公司 结合凝血因子ix和凝血因子x的双特异性抗体
EP3544628A4 (fr) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. Protéines de liaison à 4-1bb et leurs utilisations
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
KR102646046B1 (ko) 2017-01-06 2024-03-08 바이오션, 인코포레이티드 Erbb2 항체 및 이의 용도
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
EP3579871A4 (fr) 2017-02-07 2021-07-21 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
EP3625254B1 (fr) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Procédé d'humanisation fondé sur une structure tridimensionnelle
KR102643780B1 (ko) 2017-09-05 2024-03-05 이뮤노젠 아이엔씨 환자 샘플에서 엽산 수용체 1의 검출 방법
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3694552A1 (fr) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
US20190135910A1 (en) 2017-11-06 2019-05-09 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
WO2019150309A1 (fr) 2018-02-02 2019-08-08 Hammack Scott Modulateurs de gpr68 et leurs utilisations pour le traitement et la prévention de maladies
EP3752195A4 (fr) 2018-02-14 2021-11-17 Viela Bio, Inc. Anticorps dirigés contre le ligand du récepteur 3 de la tyrosine kinase 3 du sarcome de mcdonough félin (fms) (flt3l) et leurs utilisations pour le traitement de maladies auto-immunes et inflammatoires
ES3064335T3 (en) 2018-03-05 2026-04-24 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
WO2019236671A1 (fr) 2018-06-08 2019-12-12 Crystal Bioscience Inc. Animal transgénique pour produire des anticorps diversifiés ayant la même chaîne légère ii
US12428471B2 (en) 2018-06-13 2025-09-30 Crystal Bioscience Inc. Transgenic chicken that makes antibodies with long CDR-H3S stabilized by multiple disulfide bridges and diversified by gene conversion
WO2019240998A1 (fr) 2018-06-13 2019-12-19 Crystal Bioscience Inc. Production d'anticorps par modification d'un domaine variable de chaîne lourde autonome par conversion génique
WO2020014306A1 (fr) 2018-07-10 2020-01-16 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
JP7634474B2 (ja) 2018-07-18 2025-02-21 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
PL3883606T3 (pl) 2018-09-24 2023-11-27 Janssen Biotech, Inc. Bezpieczny i skuteczny sposób leczenia wrzodziejącego zapalenia jelita grubego przeciwciałami anty-il12/il23
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
MX2021005905A (es) 2018-11-20 2021-06-23 Janssen Biotech Inc Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
US20220332800A1 (en) 2018-11-20 2022-10-20 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
JP2022514561A (ja) 2018-12-18 2022-02-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
WO2020132557A1 (fr) 2018-12-21 2020-06-25 Compass Therapeutics Llc Souris transgénique exprimant une chaîne légère humaine commune
JP7689074B2 (ja) 2019-01-15 2025-06-05 ヤンセン バイオテツク，インコーポレーテツド 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
CN113330031A (zh) 2019-01-23 2021-08-31 詹森生物科技公司 用于在治疗银屑病关节炎的方法中使用的抗tnf抗体组合物
JP7635137B2 (ja) 2019-03-14 2025-02-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
WO2020183418A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Méthodes de fabrication permettant de produire des compositions d'anticorps anti-il12/il23
WO2020183269A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
AU2020243588C1 (en) 2019-03-18 2026-04-02 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CA3142665A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et methodes pour le traitement de l'arthrite psoriasique
KR20220030952A (ko) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
JP2022536088A (ja) 2019-06-04 2022-08-12 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
WO2021028752A1 (fr) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anticorps anti-tfn pour le traitement du diabète de type i
EP4100435A1 (fr) 2020-02-05 2022-12-14 Larimar Therapeutics, Inc. Protéines de liaison au peptide tat et leurs utilisations
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
JP2023524125A (ja) 2020-05-05 2023-06-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体によるクローン病の治療方法
MX2022014430A (es) 2020-05-21 2023-02-22 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
CA3189402A1 (fr) 2020-07-13 2022-01-20 Janssen Biotech, Inc. Methode sure et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps specifique anti-il23
WO2022024065A1 (fr) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
CA3193594A1 (fr) 2020-09-11 2022-03-17 Medimmune Limited Molecules therapeutiques se liant a b7-h4
EP4211663B1 (fr) 2020-09-12 2026-02-18 MedImmune Limited Méthode de notation associée à une thérapie par conjugué anticorps-anti-b7h4-médicament
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
AU2022232007A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
CA3212729A1 (fr) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Methode sure et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps specifique anti-il23
MX2023010837A (es) 2021-03-17 2023-09-29 Receptos Llc Métodos de tratamiento de la dermatitis atopica.
CA3212630A1 (fr) 2021-03-18 2022-09-22 Medimmune Limited Molecules de liaison therapeutiques
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
CN117957251A (zh) 2021-07-09 2024-04-30 詹森生物科技公司 用于制备抗tnf抗体组合物的制造方法
WO2023281466A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication permettant de produire des compositions d'anticorps anti-il12/il23
CN118139883A (zh) 2021-07-09 2024-06-04 詹森生物科技公司 用于生产抗tnf抗体组合物的制造方法
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
AU2022374890A1 (en) 2021-10-29 2024-06-13 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3238377A1 (fr) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methodes de traitement de la maladie de crohn au moyen d'un anticorps specifique anti-il23
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
CA3258517A1 (fr) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Méthode de traitement du psoriasis léger à modéré avec un anticorps spécifique d'il-23
KR20250011938A (ko) 2022-05-18 2025-01-22 얀센 바이오테크 인코포레이티드 Il23 항체에 의해 건선성 관절염을 평가 및 치료하기 위한 방법
JP2025539830A (ja) 2022-11-22 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で潰瘍性大腸炎を治療する方法
EP4667497A1 (fr) 2023-02-13 2025-12-24 Shaoxing Institute, Zhejiang University Anticorps bispécifique et son utilisation
WO2025027472A2 (fr) 2023-07-31 2025-02-06 Astrazeneca Ab Conjugués anticorps anti-cd123-médicament et leurs méthodes d'utilisation
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025262604A1 (fr) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
CA3258952A1 (fr) 2024-06-27 2026-03-01 Janssen Biotech, Inc. Méthodes de traitement de la colite ulcéreuse au moyen d’un anticorps spécifique anti-il-23

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
ATE64618T1 (de) 1982-03-15 1991-07-15 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
DE3852304T3 (de) * 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
WO1989001526A1 (fr) * 1987-08-07 1989-02-23 Genelabs Incorporated Librairie et procede de clonage par coincidence
ES2052027T5 (es) * 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.

Also Published As

Publication number Publication date
EP0472638A1 (fr) 1992-03-04
AU5673390A (en) 1990-12-18
PT94066A (pt) 1991-01-08
JP3321159B2 (ja) 2002-09-03
EP0472638A4 (en) 1992-08-19
CA2016841A1 (fr) 1990-11-16
PT94066B (pt) 1997-01-31
AU651065B2 (en) 1994-07-14
EP0472638B1 (fr) 2000-10-11
WO1990014424A1 (fr) 1990-11-29
JPH05501348A (ja) 1993-03-18

Similar Documents

Publication Publication Date Title
US6291159B1 (en) Method for producing polymers having a preselected activity
EP1026239B1 (fr) Nouveau procédé d'exploitation du répertoire immunologique
AU651065B2 (en) Method for isolating receptors having a preselected specificity
US6291158B1 (en) Method for tapping the immunological repertoire
US6291160B1 (en) Method for producing polymers having a preselected activity
US6291161B1 (en) Method for tapping the immunological repertiore
US6680192B1 (en) Method for producing polymers having a preselected activity
US6969586B1 (en) Method for tapping the immunological repertoire
EP0528881A1 (fr) Procedes de creation de phenotype a partir de populations de genes multiples
US7118866B2 (en) Heterodimeric receptor libraries using phagemids
CN107922950B (zh) T细胞受体文库
IE84214B1 (en) Heterodimeric receptor libraries using phagemids
KR20070050927A (ko) 결합 분자

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry